T
Thomas E. Goodwin Data-verified
Affiliation confirmed via AI analysis of OpenAlex, ORCID, and web sources.
High Impact
Researcher
faculty
22 h-index
107 pubs
1,490 cited
Research Areas
Links
Biography and Research Information
OverviewAI-generated summary
Thomas E. Goodwin's research program investigates the metabolic pathways and therapeutic potential of novel drug compounds, particularly in the context of hematological malignancies and other cancers. His work has focused on dihydroorotate dehydrogenase (DHODH) inhibitors, such as Hosu-53, examining their efficacy as monotherapies and in combination with targeted therapies like CD47 blockade. These studies have explored the impact of DHODH inhibition on immune cell metabolism, including its role in modulating T cell responses to limit graft-versus-host disease while preserving graft-versus-leukemia activity.
Goodwin's recent publications also extend to the study of animal communication, specifically investigating how olfactory cues encode identity and group membership in African elephants. This work utilizes techniques such as gas chromatography-mass spectrometry to analyze complex odor profiles. His research group is active in these areas, contributing to a body of work that includes over 100 publications and has garnered significant citations, reflected in his h-index of 22. He has collaborated with researchers at Hendrix College on shared publications.
Metrics
- h-index: 22
- Publications: 107
- Citations: 1,490
Selected Publications
-
Abstract 6902: Promising therapeutic effects of pyrimidine synthesis inhibition by a novel dihydroorotate dehydrogenase inhibitor in small cell lung cancer (2025)
-
DHODH inhibition alters T cell metabolism limiting acute graft-versus<i>-</i>host disease while retaining <i>graft-</i>versus<i>-</i>leukemia response (2025)
-
DHODH Inhibition Modulates T Cell Metabolism, Selectively Impairs Effector T Cell Response, Limiting Gvhd While Preserving GVL. (2025)
-
Pyrimidine depletion enhances targeted and immune therapy combinations in acute myeloid leukemia (2024)
-
The Potent Dihydroorotate Dehydrogenase Inhibitor, Hosu-53, Exhibits Compelling Monotherapy Efficacy in Multiple Myeloma and Augments CD47 Targeted Therapy (2023)
-
Hosu-53, a Novel Potent Dihydroorotate Dehydrogenase Inhibitor Accentuates CD47 Blockade Therapy Resulting in Long Term Survival in Acute Myeloid Leukemia (2022)
-
Preclinical Development of Hosu-53, a Novel Potent Dihydroorotate Dehydrogenase Inhibitor with Impressive Single Agent Efficacy and Combination Approaches in Hematological Malignancy (2022)
-
A pachyderm perfume: odour encodes identity and group membership in African elephants (2022)
Collaboration Network
Top Collaborators
Sandip Vibhute
The Ohio State University (US)
9 shared publications
- Pyrimidine depletion enhances targeted and immune therapy combinations in acute myeloid leukemia
- The Potent Dihydroorotate Dehydrogenase Inhibitor, Hosu-53, Exhibits Compelling Monotherapy Efficacy in Multiple Myeloma and Augments CD47 Targeted Therapy
- Abstract 2335: DHODH inhibition modulates T cell metabolism reducing GVHD and prevents relapse following allogeneic HCT
- Abstract 1060: Introducing a novel DHODH inhibitor with superior <i>in vivo</i> activity as monotherapy or in novel combination regimen with immunotherapy for hematological malignancies
- Preclinical Development of Hosu-53, a Novel Potent Dihydroorotate Dehydrogenase Inhibitor with Impressive Single Agent Efficacy and Combination Approaches in Hematological Malignancy
Showing 5 of 9 shared publications
Chad Bennett
The Ohio State University (US)
8 shared publications
- The Potent Dihydroorotate Dehydrogenase Inhibitor, Hosu-53, Exhibits Compelling Monotherapy Efficacy in Multiple Myeloma and Augments CD47 Targeted Therapy
- Abstract 2335: DHODH inhibition modulates T cell metabolism reducing GVHD and prevents relapse following allogeneic HCT
- Abstract 1060: Introducing a novel DHODH inhibitor with superior <i>in vivo</i> activity as monotherapy or in novel combination regimen with immunotherapy for hematological malignancies
- Preclinical Development of Hosu-53, a Novel Potent Dihydroorotate Dehydrogenase Inhibitor with Impressive Single Agent Efficacy and Combination Approaches in Hematological Malignancy
- Hosu-53, a Novel Potent Dihydroorotate Dehydrogenase Inhibitor Accentuates CD47 Blockade Therapy Resulting in Long Term Survival in Acute Myeloid Leukemia
Showing 5 of 8 shared publications
Ola A. Elgamal
University of Cincinnati (US)
8 shared publications
- Pyrimidine depletion enhances targeted and immune therapy combinations in acute myeloid leukemia
- The Potent Dihydroorotate Dehydrogenase Inhibitor, Hosu-53, Exhibits Compelling Monotherapy Efficacy in Multiple Myeloma and Augments CD47 Targeted Therapy
- Abstract 2335: DHODH inhibition modulates T cell metabolism reducing GVHD and prevents relapse following allogeneic HCT
- Abstract 1060: Introducing a novel DHODH inhibitor with superior <i>in vivo</i> activity as monotherapy or in novel combination regimen with immunotherapy for hematological malignancies
- Preclinical Development of Hosu-53, a Novel Potent Dihydroorotate Dehydrogenase Inhibitor with Impressive Single Agent Efficacy and Combination Approaches in Hematological Malignancy
Showing 5 of 8 shared publications
Erin Hertlein
University of Cincinnati (US)
8 shared publications
- The Potent Dihydroorotate Dehydrogenase Inhibitor, Hosu-53, Exhibits Compelling Monotherapy Efficacy in Multiple Myeloma and Augments CD47 Targeted Therapy
- Abstract 2335: DHODH inhibition modulates T cell metabolism reducing GVHD and prevents relapse following allogeneic HCT
- Abstract 1060: Introducing a novel DHODH inhibitor with superior <i>in vivo</i> activity as monotherapy or in novel combination regimen with immunotherapy for hematological malignancies
- Preclinical Development of Hosu-53, a Novel Potent Dihydroorotate Dehydrogenase Inhibitor with Impressive Single Agent Efficacy and Combination Approaches in Hematological Malignancy
- Hosu-53, a Novel Potent Dihydroorotate Dehydrogenase Inhibitor Accentuates CD47 Blockade Therapy Resulting in Long Term Survival in Acute Myeloid Leukemia
Showing 5 of 8 shared publications
John C. Byrd
University of Cincinnati (US)
5 shared publications
- The Potent Dihydroorotate Dehydrogenase Inhibitor, Hosu-53, Exhibits Compelling Monotherapy Efficacy in Multiple Myeloma and Augments CD47 Targeted Therapy
- Abstract 2335: DHODH inhibition modulates T cell metabolism reducing GVHD and prevents relapse following allogeneic HCT
- Preclinical Development of Hosu-53, a Novel Potent Dihydroorotate Dehydrogenase Inhibitor with Impressive Single Agent Efficacy and Combination Approaches in Hematological Malignancy
- Hosu-53, a Novel Potent Dihydroorotate Dehydrogenase Inhibitor Accentuates CD47 Blockade Therapy Resulting in Long Term Survival in Acute Myeloid Leukemia
- Abstract 6902: Promising therapeutic effects of pyrimidine synthesis inhibition by a novel dihydroorotate dehydrogenase inhibitor in small cell lung cancer
Susheela Tridandapani
4 shared publications
- Pyrimidine depletion enhances targeted and immune therapy combinations in acute myeloid leukemia
- The Potent Dihydroorotate Dehydrogenase Inhibitor, Hosu-53, Exhibits Compelling Monotherapy Efficacy in Multiple Myeloma and Augments CD47 Targeted Therapy
- Abstract 1060: Introducing a novel DHODH inhibitor with superior <i>in vivo</i> activity as monotherapy or in novel combination regimen with immunotherapy for hematological malignancies
- Hosu-53, a Novel Potent Dihydroorotate Dehydrogenase Inhibitor Accentuates CD47 Blockade Therapy Resulting in Long Term Survival in Acute Myeloid Leukemia
Christopher C. Coss
The Ohio State University (US)
4 shared publications
- Pyrimidine depletion enhances targeted and immune therapy combinations in acute myeloid leukemia
- Abstract 1060: Introducing a novel DHODH inhibitor with superior <i>in vivo</i> activity as monotherapy or in novel combination regimen with immunotherapy for hematological malignancies
- Preclinical Development of Hosu-53, a Novel Potent Dihydroorotate Dehydrogenase Inhibitor with Impressive Single Agent Efficacy and Combination Approaches in Hematological Malignancy
- Abstract 6902: Promising therapeutic effects of pyrimidine synthesis inhibition by a novel dihydroorotate dehydrogenase inhibitor in small cell lung cancer
Jeffrey Patrick
4 shared publications
- Pyrimidine depletion enhances targeted and immune therapy combinations in acute myeloid leukemia
- The Potent Dihydroorotate Dehydrogenase Inhibitor, Hosu-53, Exhibits Compelling Monotherapy Efficacy in Multiple Myeloma and Augments CD47 Targeted Therapy
- Preclinical Development of Hosu-53, a Novel Potent Dihydroorotate Dehydrogenase Inhibitor with Impressive Single Agent Efficacy and Combination Approaches in Hematological Malignancy
- Hosu-53, a Novel Potent Dihydroorotate Dehydrogenase Inhibitor Accentuates CD47 Blockade Therapy Resulting in Long Term Survival in Acute Myeloid Leukemia
Kara M. Braunreiter
The Ohio State University (US)
3 shared publications
- Abstract 2335: DHODH inhibition modulates T cell metabolism reducing GVHD and prevents relapse following allogeneic HCT
- DHODH Inhibition Modulates T Cell Metabolism, Selectively Impairs Effector T Cell Response, Limiting Gvhd While Preserving GVL.
- DHODH inhibition alters T cell metabolism limiting acute graft-versus<i>-</i>host disease while retaining <i>graft-</i>versus<i>-</i>leukemia response
Yandi Gao
The Ohio State University (US)
3 shared publications
- Abstract 2335: DHODH inhibition modulates T cell metabolism reducing GVHD and prevents relapse following allogeneic HCT
- DHODH Inhibition Modulates T Cell Metabolism, Selectively Impairs Effector T Cell Response, Limiting Gvhd While Preserving GVL.
- DHODH inhibition alters T cell metabolism limiting acute graft-versus<i>-</i>host disease while retaining <i>graft-</i>versus<i>-</i>leukemia response
Parvathi Ranganathan
The Ohio State University (US)
3 shared publications
- Abstract 2335: DHODH inhibition modulates T cell metabolism reducing GVHD and prevents relapse following allogeneic HCT
- DHODH Inhibition Modulates T Cell Metabolism, Selectively Impairs Effector T Cell Response, Limiting Gvhd While Preserving GVL.
- DHODH inhibition alters T cell metabolism limiting acute graft-versus<i>-</i>host disease while retaining <i>graft-</i>versus<i>-</i>leukemia response
Sharyn D. Baker
Comprehensive Blood & Cancer Center (US)
3 shared publications
- Pyrimidine depletion enhances targeted and immune therapy combinations in acute myeloid leukemia
- Abstract 1060: Introducing a novel DHODH inhibitor with superior <i>in vivo</i> activity as monotherapy or in novel combination regimen with immunotherapy for hematological malignancies
- Preclinical Development of Hosu-53, a Novel Potent Dihydroorotate Dehydrogenase Inhibitor with Impressive Single Agent Efficacy and Combination Approaches in Hematological Malignancy
Gerard Hilinski
The Ohio State University (US)
3 shared publications
- The Potent Dihydroorotate Dehydrogenase Inhibitor, Hosu-53, Exhibits Compelling Monotherapy Efficacy in Multiple Myeloma and Augments CD47 Targeted Therapy
- Abstract 1060: Introducing a novel DHODH inhibitor with superior <i>in vivo</i> activity as monotherapy or in novel combination regimen with immunotherapy for hematological malignancies
- Hosu-53, a Novel Potent Dihydroorotate Dehydrogenase Inhibitor Accentuates CD47 Blockade Therapy Resulting in Long Term Survival in Acute Myeloid Leukemia
Blaise Stearns
University of Cincinnati Medical Center (US)
3 shared publications
- Pyrimidine depletion enhances targeted and immune therapy combinations in acute myeloid leukemia
- The Potent Dihydroorotate Dehydrogenase Inhibitor, Hosu-53, Exhibits Compelling Monotherapy Efficacy in Multiple Myeloma and Augments CD47 Targeted Therapy
- Hosu-53, a Novel Potent Dihydroorotate Dehydrogenase Inhibitor Accentuates CD47 Blockade Therapy Resulting in Long Term Survival in Acute Myeloid Leukemia
Lotus Neidemire-Colley
The Ohio State University (US)
2 shared publications
- Abstract 2335: DHODH inhibition modulates T cell metabolism reducing GVHD and prevents relapse following allogeneic HCT
- DHODH inhibition alters T cell metabolism limiting acute graft-versus<i>-</i>host disease while retaining <i>graft-</i>versus<i>-</i>leukemia response
Similar Researchers
Based on overlapping research topics
Mouad Abdulrahim
Hendrix College
Acute Myeloid Leukemia Research
Cancer Treatment and Pharmacology
Metabolism and Genetic Disorders
Ankur Varma
University of Arkansas for Medical Sciences
Acute Myeloid Leukemia Research
Cancer Treatment and Pharmacology
Metabolism and Genetic Disorders
Rick D. Edmondson
University of Arkansas for Medical Sciences
Cancer Treatment and Pharmacology
Metabolism and Genetic Disorders
Metabolomics and Mass Spectrometry Studies
Gaven K. Smart
University of Arkansas at Fayetteville
Cancer Treatment and Pharmacology
Metabolism and Genetic Disorders
Immune Response and Inflammation
Elisabeth M. Davis
University of Arkansas for Medical Sciences
Metabolism and Genetic Disorders
Immune Response and Inflammation
Health and Medical Research Impacts
Lori Dean
University of Arkansas for Medical Sciences
Metabolism and Genetic Disorders
Immune Response and Inflammation
Health and Medical Research Impacts